Biofrontera Pharma Gmbh

Biofrontera Pharma GmbH is a biopharmaceutical company specialized in the development and commercialization of dermatological products. Founded in 2006 and based in Leverkusen, Germany, the company is focused on innovative therapies for skin diseases, particularly in the field of photodynamic therapy (PDT) for actinic keratosis and other skin cancers. Biofrontera’s flagship product, Ameluz, is a prescription drug that combines aminolevulinic acid with a light for effective treatment. The company has a strong commitment to research and development, aimed at providing patients with effective and safe treatment options. With a growing portfolio and international market presence, Biofrontera Pharma GmbH aims to enhance the quality of life for patients with dermatological conditions.